Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
First-in-human study of the cancer peptide vaccine, TAS0313, in patients with advanced solid tumors: Phase I dose-finding part results.
Authors
Noboru Yamamoto
Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
Noboru Yamamoto, Jun Sato, Shunsuke Kondo, Takafumi Koyama, Kan Yonemori, Satoru Iwasa, Toshio Shimizu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Modulating Innate Immunity
Clinical Trial Registration Number
JapicCTI-183824
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr 73)
Abstract #
73
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE).
First Author: Kyriakos P. Papadopoulos
Poster
2020 ASCO Virtual Scientific Program
A phase I study to evaluate the T-cell engager AMV564 alone and in combination with pembrolizumab in subjects with advanced solid tumors.
First Author: Alexander Starodub
Poster
2020 Gastrointestinal Cancers Symposium
Phase I study of a new concept cancer vaccine composed artificial intelligence (AI)-designed shared-antigen peptides plus combined synergistically activating antigen-specific CTL reaction (CYT001) in patients with advanced hepatocellular carcinoma (CRESCENT 1).
First Author: Sadahisa Ogasawara
Poster
2018 Gastrointestinal Cancers Symposium
Phase 1 studies of 3- and 6-peptide vaccine cocktail derived from GPC3, WDRPUH, and NEIL3 in patients with advanced hepatocellular carcinoma (HCC).
First Author: Masafumi Ikeda